Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 21:9:1707-13.
doi: 10.2147/OTT.S98666. eCollection 2016.

Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study

Jia-Yuan Sun  1 , San-Gang Wu  2 , Feng-Yan Li  1 , Huan-Xin Lin  1 , Zhen-Yu He  1
Affiliations

Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study

Jia-Yuan Sun et al. Onco Targets Ther. .

Abstract

Background: To assess the prognostic value of progesterone receptor (PR) expression in patients with hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer subgroups.

Methods: A retrospective review of breast cancer patients who underwent mastectomy or breast-conserving surgery between January 1998 and December 2007 was performed. The prognostic impact of PR status on disease-free survival (DFS) was analyzed.

Results: Of the 1,301 patients included in this study, the median follow-up time was 64 months, and the median age was 46 years. There were 18.4% of patients (n=219) with PR negative (PR-) cancer. Women with PR-breast cancer were more likely to be postmenopausal (P<0.001) and have pN3 stage (P=0.031) and Stage III (P=0.049) cancer. Cox regression univariate and multivariate analysis showed that PR status was a significant prognostic factor for DFS. Patients with PR- status had poorer DFS (hazard ratio =1.626, 95% confidence interval =1.060-2.497, P=0.026). The 5-year DFS for patients with PR- and PR+ breast cancer was 79.4% and 86.2%, respectively, and the 8-year DFS for patients with PR- and PR+ breast cancer was 69.6% and 78.1%, respectively (P=0.012). A significant difference in DFS was observed between PR- and PR+ disease in patients with node-negative cancer, but was not for patients with lymph node metastasis (P=0.242). In premenopausal patients, DFS varied significantly by PR status (P=0.049). A marginally significant difference in DFS between the PR- and PR+ disease was seen in postmenopausal patients (log rank P=0.065).

Conclusion: Lack of PR expression is associated with worse survival in patients with hormone receptor-positive and HER2-negative breast cancer subgroups.

Keywords: breast cancer; breast cancer subtype; progesterone receptor; prognosis; recurrence.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier plot of disease-free survival by PR status. Abbreviation: PR, progesterone receptor.
Figure 2
Figure 2
Kaplan–Meier plot of disease-free survival by PR status in (A) lymph-node-negative patients and (B) lymph-node-positive patients. Abbreviation: PR, progesterone receptor.
Figure 3
Figure 3
Kaplan–Meier plot of disease-free survival by PR status in (A) premenopausal patients and (B) postmenopausal patients. Abbreviation: PR, progesterone receptor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–10874. - PMC - PubMed
    1. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–2502. - PubMed
    1. Martín M, Rodríguez-Lescure A, Ruiz A, et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat. 2010;123(1):149–157. - PubMed
    1. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27(8):1168–1176. - PMC - PubMed
    1. Wu SG, He ZY, Li Q, et al. Predictive value of breast cancer molecular subtypes in Chinese patients with four or more positive nodes after postmastectomy radiotherapy. Breast. 2012;21(5):657–661. - PubMed